Venus Medtech Receives S$37M Investment from Goldman Sachs

▤ Summary

The investment will support the company’s R&D as well as commercialization of cardiac valve products.Led by General Manager Zi Zhenjun, Venus Medtech has developed the Venus A-Valve, with independent intellectual property rights, a transcatheter aortic valve solution meeting China Food and Drug Administration clinical requirement.Venus P-Valve is designed for interventional therapy for patients with severe pulmonary regurgitation following surgery to repair Tetralogy of Fallot.Enrollment of patients for a clinical trial is nearly completed.Venus Medtech plans to start patient enrollment for a pending EU approval-oriented clinical research program in the first half of 2016.

▦ Linked Companies